The Second Circuit has denied en banc review of a so-called "pay to delay" deal. The unusual route and importance of this case, involving Cipro, the most prescribed antibiotic in the world, is at this link (prior Appellate Daily coverage).
Today's en banc denial is here and related Reuters coverage is here.
